Product logins

Find logins to all Clarivate products below.


Blog: Biopharma

Here you will find relevant articles and insight into all Clarivate related products and news.

The competitive signals hiding in plain sight for biopharma The competitive signals hiding in plain sight for biopharma
Blog May 8, 2026
The competitive signals hiding in plain sight for biopharma
Biopharma Business Development Clinical trials
Five lessons learned deploying agentic AI in the life sciences Five lessons learned deploying agentic AI in the life sciences
Blog April 30, 2026
Five lessons learned deploying agentic AI in the life sciences
AI
Target selection and safety assessment: Navigating early decisions that shape drug development Target selection and safety assessment: Navigating early decisions that shape drug development
Blog March 27, 2026
Target selection and safety assessment: Navigating early decisions that shape drug development
Development Pharma Regulatory
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
Blog March 26, 2026
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
GLP-1 Metabolic
Why longevity might be biopharma's next big thing: The science and business converge Why longevity might be biopharma's next big thing: The science and business converge
Blog March 2, 2026
Why longevity might be biopharma's next big thing: The science and business converge
Gerontology
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
Biopharma Biotech Clinical trials
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Relacorilant:  when evidence meets the established evidence bar Relacorilant:  when evidence meets the established evidence bar
Blog February 24, 2026
Relacorilant: when evidence meets the established evidence bar
FDA Regulatory Safety

Biopharma

Blog November 21, 2017
Notable licensing deals in the biopharma industry in Q3 2017
Blog October 10, 2017
Pharma’s approach to market access facing digital disruption, study finds
Blog October 10, 2017
CAR T-cell gene therapies enter the U.S. market
Blog September 27, 2017
Digitizing pharma’s pivot to payer marketing
Blog September 12, 2017
Fixing pharma’s big problem with HCP portals and customer experience
The blockbuster PARP inhibitor fight intensifies: Focus on ovarian cancer The blockbuster PARP inhibitor fight intensifies: Focus on ovarian cancer
Blog August 31, 2017
The blockbuster PARP inhibitor fight intensifies: Focus on ovarian cancer
Blog August 23, 2017
Is the FDA’s carrot and stick approach to pediatric drugs working?
Blog August 8, 2017
Second Remicade biosimilar offers glimpse of competitive U.S. market in the future
Blog July 19, 2017
Lung cancer – continued progress in personalized care
Blog May 16, 2017
Victories in Huntington’s disease few and far between, but resolve remains undimmed